Preemptive therapy versus universal prophylaxis: Time for reconciliation?

被引：2
|
作者：
Kampouri, Eleftheria [1 ]
Manuel, Oriol [2 ,3 ,4 ,5 ]
机构：
[1] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[2] Lausanne Univ Hosp, Infect Dis Serv & Transplantat Ctr, Lausanne, Switzerland
[3] Univ Lausanne, Lausanne, Switzerland
[4] Lausanne Univ Hosp, Infect Dis Serv & Transplantat Ctr, BH10-549,Bugnon 46, CH-1011 Lausanne, Switzerland
[5] Univ Lausanne, BH10-549,Bugnon 46, CH-1011 Lausanne, Switzerland
来源：
TRANSPLANT INFECTIOUS DISEASE | 2023年 / 25卷 / 02期
关键词：
ONSET CYTOMEGALOVIRUS DISEASE; LIVER-TRANSPLANT RECIPIENTS; ANTIVIRAL PROPHYLAXIS;
D O I：
10.1111/tid.14014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prophylaxis Versus Preemptive Therapy for Prevention of the Consequences of Cytomegalovirus Infection in Transplant Recipients: A Still Unresolved Issue
    Potena, Luciano
    Grigioni, Francesco
    Magnani, Gaia
    Branzi, Angelo
    TRANSPLANTATION, 2009, 87 (02) : 305 - 306
  • [22] CMV INFECTION FOLLOWING LIVER TRANSPLANTATION: PREEMPTIVE THERAPY OR PROPHYLAXIS
    Lindner, K.
    Anthoni, C.
    Hoelzen, J. P.
    Beckebaum, S.
    Wolters, H.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 40 - 40
  • [23] Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?
    Ostrosky-Zeichner, L
    CRITICAL CARE MEDICINE, 2004, 32 (12) : 2552 - 2553
  • [24] Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis
    Zamora, Danniel
    Dasgupta, Sayan
    Stevens-Ayers, Terry
    Edmison, Bradley
    Winston, Drew J.
    Razonable, Raymund R.
    Mehta, Aneesh K.
    Lyon, G. Marshall
    Boeckh, Michael
    Singh, Nina
    Koelle, David M.
    Limaye, Ajit P.
    JCI INSIGHT, 2024, 9 (18)
  • [25] Prophylaxis versus preemptive protocols for CMV:: Do they impact graft survival?
    Miller, G. G.
    Kaplan, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (05) : 913 - 914
  • [26] Pre-emptive CMV therapy versus universal CMV prophylaxis in renal transplant recipients
    Rebecca Kelsey
    Nature Reviews Nephrology, 2012, 8 (11) : 614 - 614
  • [27] Preemptive Therapy Versus Valgancyclovir Prophylaxis in Cytomegalovirus-positive Kidney Transplant Recipients Receiving Antithymocyte Globulin Induction
    Couzi, L.
    Helou, S.
    Bachelet, T.
    Martin, S.
    Moreau, K.
    Morel, D.
    Lafon, M. E.
    Garrigue, I.
    Merville, P.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (09) : 2809 - 2813
  • [28] Randomized trial of preemptive valganciclovir therapy versus valacyclovir prophylaxis for the management of cytomegalovirus infection in kidney transplant recipients.
    Reischig, Tomas
    Jindra, Pavel
    Klaboch, Jan
    Svecova, Miroslava
    Hes, Ondrej
    Treska, Vladislav
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 506 - 506
  • [29] CMV VALGANCICLOVIR PROPHYLAXIS VERSUS PREEMPTIVE THERAPY AFTER RENAL TRANSPLANTATION: TWO YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL
    Witzke, O.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 31 - 32
  • [30] Preemptive Therapy Versus Valganciclovir Prophylaxis in CMV R plus Kidney Transplant Recipients Receiving Antithymocyte Globulin Induction
    Couzi, L.
    Helou, S.
    Bachelet, T.
    Martin, S.
    Moreau, K.
    Morel, D.
    Lafon, M. -E.
    Garrigue, I.
    Merville, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 469 - 469
12345